ABSTRACT
AIM: The aim of this study was to assess visfatin expression and its effect on human telomerase gene expression in AGS gastric cancer cell line. MATERIALS AND METHODS: In this study, human gastric cancer (AGS) cell line was established as an in vitro model. Reverse transcription polymerase chain reaction (RT‑PCR) and enzyme‑linked immunosorbent assay was performed to show that visfatin expression in messenger ribonucleic acid (mRNA) and protein level respectively. After stimulating with increasing concentrations of visfatin for times of 24 h and 48 h, cell proliferation was assessed by 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) assay. In order to investigate telomerase gene expression affected by visfatin in AGS cell line, total RNA was extracted and complementary deoxyribonucleic acid was synthesized buy using commercially available kits. Expression of human telomerase reverse transcriptase (hTERT) mRNA was carried out by real‑time RT‑PCR. RESULTS: After visfatin treatment gastric cell line proliferation was enhanced and was increased the expression of hTERT. CONCLUSIONS: The obtained data showed that visfatin induces endogenously gastric cancer cell proliferation and increases telomerase (hTERT) gene expression, as a cancer gene. Based on this study, it is suggested that expression of this adipocytokine protein in real samples could be biomarker for gastric cancer.
ABSTRACT
Diabetes is a common endocrine disease and its complications are major stimuli for the enhancement of efforts towards its control. At present, glycosylated hemoglobin [HbA1c] is used for long term control of glucose levels in diabetic patients, but due to lack of availability of a standard control method, recent findings suggest that insulin-like growth factor-I [IGF-I] may be used as a biomarker for glycaemic control. The aim of this study was to examine the correlation between IGF-I and glycaemic control measured as fasting plasma glucose [FPG] and HbA1c in Type 1 diabetes
Materials and Methods: we designed a cross-sectional case-control study with systematic random sampling. The study included 26 newly diagnosed patients with Type 1 diabetes [15 male and 11 female; mean age 23.7+/-9.1 years] and 26 healthy controls [9 male and 17 female; mean age 24.1+/-4.4 years]. The concentrations of FPG, IGF-I, HbA1c and IGF-binding protein-3 [IGFBP-3] were measured in both groups. FPG was measured by the enzymatic glucose oxidase method and the colorimetric method was used to measure HbA1c. Determination of serum IGF-I and IGFBP-3 total levels was carried out using immunoassay. P<0.05 was considered as statistically significant
Results: the mean value of IGF-I concentration in Type 1 diabetics was significantly lower than in controls [p<0.05]. No correlation was found between IGF-I and HbA1c in the patients
Conclusion: our data shows that total IGF-I levels are low in patients with Type 1 diabetes. No relationship was found between IGF-I and glycaemic control. However, more detailed intensive studies to further investigate this relationship are recommended